drugset / Trial / NCT04944862
A Study of CDX-0159 in Patients With Prurigo Nodularis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to explore the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 (barzolvolimab) in patients with Prurigo Nodularis.
Timeline
- Start
- 2021-11-08
- Primary completion
- 2023-07-31
- Completion
- 2023-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | barzolvolimab | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | barzolvolimab | Monoclonal antibody | 3 mg/kg | Intravenous |